Surrozen, Inc. Warrant (SRZNW) Stock Price
SRZNWStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.92
SRZNW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-103.62%
Price vs S&P 500 (4W)-94.49%
VGM Score1.09
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SRZNWSurrozen, Inc. Warrant | — | — | F | $0.00 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Surrozen, Inc. Warrant
Surrozen Inc is a clinical-stage biotechnology company developing therapies that modulate the Wnt pathway to promote tissue repair across multiple organ systems. The company is advancing a pipeline of drug candidates, including SZN-1326, SZN-413, and SZN-043, each targeting distinct mechanisms to maximize therapeutic potential. Surrozen's focused approach to Wnt pathway biology aims to address unmet clinical needs in regenerative medicine and tissue homeostasis.